AstraZeneca and Daiichi Sankyo’s Datroway drug has been approved in the U.S. to treat adult patients with non-small cell lung cancer. British pharmaceutical company AstraZeneca said Tuesday that the ...

AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy in this ...

Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.

Daiichi Sankyo (TSE: 4568) and Merck (known as MSD outside of the United States and Canada) (NYSE: MRK) have entered into a global development and com ...

On top of being Enhertu’s first foray into DTC marketing, the campaign represents “the first DTC that we’ve developed at Daiichi Sankyo for any of our oncology products," Dan Switzer, head ...

Daiichi Sankyo and MSD have broadened their partnership for the global joint development and commercialisation of three DXd-based antibody-drug conjugates (ADCs). DXd is Daiichi Sankyo's ...

Additionally, Daiichi Sankyo is banking on its ADC platform to target specific antigens and proteins as it explores more treatment options in its pipeline, including patritumab deruxtecan, ifinatamab ...

Daiichi Sankyo Company, Limited leads in ADC tech with Enhertu, strong partnerships, revenue growth, and global market leadership. Click to know more on why DSNKY is a Buy.

PE: What are the benefits that Daiichi Sankyo sees from participating in this? Switzer: I'll start with the benefits internally as an organization. We are a global pharmaceutical company, but our ...

AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients ...